Switch theme
Sign up to access all valuation multiples
Hangzhou Tigermed Consulting Co Ltd is a China-based Contract Research Organization. The company's offered services include bioanalytical, medical writing, biostatistical analysis, and medical imaging. The therapeutic areas of the company include Infections, Hematology, Cardiovascular, Endocrinology, Rheumatology, Nephrology, and Central Nervous System (CNS) among others.
2004
10.2K+
LTM Revenue $942M
LTM EBITDA $183M
$5.8B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Hangzhou Tigermed has a last 12-month revenue (LTM) of $942M and a last 12-month EBITDA of $183M.
In the most recent fiscal year, Hangzhou Tigermed achieved revenue of $916M and an EBITDA of $157M.
Hangzhou Tigermed expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Hangzhou Tigermed valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $942M | XXX | $916M | XXX | XXX | XXX |
| Gross Profit | $326M | XXX | $311M | XXX | XXX | XXX |
| Gross Margin | 35% | XXX | 34% | XXX | XXX | XXX |
| EBITDA | $183M | XXX | $157M | XXX | XXX | XXX |
| EBITDA Margin | 19% | XXX | 17% | XXX | XXX | XXX |
| EBIT | $134M | XXX | $148M | XXX | XXX | XXX |
| EBIT Margin | 14% | XXX | 16% | XXX | XXX | XXX |
| Net Profit | $91.3M | XXX | $56.2M | XXX | XXX | XXX |
| Net Margin | 10% | XXX | 6% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $25.0M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Hangzhou Tigermed's stock price is CNY 47 (or $6).
Hangzhou Tigermed has current market cap of CNY 40.3B (or $5.6B), and EV of CNY 41.6B (or $5.8B).
See Hangzhou Tigermed trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5.8B | $5.6B | XXX | XXX | XXX | XXX | $0.11 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Hangzhou Tigermed has market cap of $5.6B and EV of $5.8B.
Hangzhou Tigermed's trades at 6.3x EV/Revenue multiple, and 36.8x EV/EBITDA.
Equity research analysts estimate Hangzhou Tigermed's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Hangzhou Tigermed has a P/E ratio of 61.2x.
See valuation multiples for Hangzhou Tigermed and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $5.6B | XXX | $5.6B | XXX | XXX | XXX |
| EV (current) | $5.8B | XXX | $5.8B | XXX | XXX | XXX |
| EV/Revenue | 6.1x | XXX | 6.3x | XXX | XXX | XXX |
| EV/EBITDA | 31.6x | XXX | 36.8x | XXX | XXX | XXX |
| EV/EBIT | 43.2x | XXX | 39.0x | XXX | XXX | XXX |
| EV/Gross Profit | 17.7x | XXX | n/a | XXX | XXX | XXX |
| P/E | 61.2x | XXX | 99.4x | XXX | XXX | XXX |
| EV/FCF | 44.6x | XXX | 56.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialHangzhou Tigermed's last 12 month revenue growth is 8%
Hangzhou Tigermed's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $16K for the same period.
Hangzhou Tigermed's rule of 40 is 48% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Hangzhou Tigermed's rule of X is 40% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Hangzhou Tigermed and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 8% | XXX | 9% | XXX | XXX | XXX |
| EBITDA Margin | 19% | XXX | 17% | XXX | XXX | XXX |
| EBITDA Growth | 25% | XXX | -27% | XXX | XXX | XXX |
| Rule of 40 | 48% | XXX | 25% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 40% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $16K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 1% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 4% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 18% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Jubilant Pharmova | XXX | XXX | XXX | XXX | XXX | XXX |
| Biocon | XXX | XXX | XXX | XXX | XXX | XXX |
| Syngene International | XXX | XXX | XXX | XXX | XXX | XXX |
| Dishman Carbogen Amics | XXX | XXX | XXX | XXX | XXX | XXX |
| Cohance Lifesciences | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Hangzhou Tigermed acquired XXX companies to date.
Last acquisition by Hangzhou Tigermed was XXXXXXXX, XXXXX XXXXX XXXXXX . Hangzhou Tigermed acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Hangzhou Tigermed founded? | Hangzhou Tigermed was founded in 2004. |
| Where is Hangzhou Tigermed headquartered? | Hangzhou Tigermed is headquartered in China. |
| How many employees does Hangzhou Tigermed have? | As of today, Hangzhou Tigermed has 10.2K+ employees. |
| Is Hangzhou Tigermed publicy listed? | Yes, Hangzhou Tigermed is a public company listed on SHE. |
| What is the stock symbol of Hangzhou Tigermed? | Hangzhou Tigermed trades under 300347 ticker. |
| When did Hangzhou Tigermed go public? | Hangzhou Tigermed went public in 2012. |
| Who are competitors of Hangzhou Tigermed? | Similar companies to Hangzhou Tigermed include e.g. Jubilant Pharmova, Biocon, Syngene International, Dishman Carbogen Amics. |
| What is the current market cap of Hangzhou Tigermed? | Hangzhou Tigermed's current market cap is $5.6B |
| What is the current revenue of Hangzhou Tigermed? | Hangzhou Tigermed's last 12 months revenue is $942M. |
| What is the current revenue growth of Hangzhou Tigermed? | Hangzhou Tigermed revenue growth (NTM/LTM) is 8%. |
| What is the current EV/Revenue multiple of Hangzhou Tigermed? | Current revenue multiple of Hangzhou Tigermed is 6.1x. |
| Is Hangzhou Tigermed profitable? | Yes, Hangzhou Tigermed is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Hangzhou Tigermed? | Hangzhou Tigermed's last 12 months EBITDA is $183M. |
| What is Hangzhou Tigermed's EBITDA margin? | Hangzhou Tigermed's last 12 months EBITDA margin is 19%. |
| What is the current EV/EBITDA multiple of Hangzhou Tigermed? | Current EBITDA multiple of Hangzhou Tigermed is 31.6x. |
| What is the current FCF of Hangzhou Tigermed? | Hangzhou Tigermed's last 12 months FCF is $130M. |
| What is Hangzhou Tigermed's FCF margin? | Hangzhou Tigermed's last 12 months FCF margin is 14%. |
| What is the current EV/FCF multiple of Hangzhou Tigermed? | Current FCF multiple of Hangzhou Tigermed is 44.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
